Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) - Pipeline Review, H1 2016

  • ID: 3743749
  • Drug Pipelines
  • 181 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Agenus, Inc.
  • GlaxoSmithKline Plc
  • MacroGenics, Inc.
  • Merus B.V.
  • Sutro Biopharma, Inc.
  • Theravectys SA
  • MORE
Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) - Pipeline Review, H1 2016

Summary

‘Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) - Pipeline Review, H1 2016’, provides in depth analysis on Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) targeted pipeline therapeutics.

The report provides comprehensive information on the Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1)
- The report reviews Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Agenus, Inc.
  • GlaxoSmithKline Plc
  • MacroGenics, Inc.
  • Merus B.V.
  • Sutro Biopharma, Inc.
  • Theravectys SA
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) Overview

Therapeutics Development

Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) - Products under Development by Stage of Development

Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) - Products under Development by Therapy Area

Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) - Products under Development by Indication

Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Unknown Stage Products

Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) - Products under Development by Companies

Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) - Products under Development by Universities/Institutes

Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) - Companies Involved in Therapeutics Development

Agenus, Inc.

Aurigene Discovery Technologies Limited

BeiGene, Ltd.

Cellular Biomedicine Group, Inc.

CytomX Therapeutics, Inc.

Enumeral Biomedical Holdings, Inc.

GlaxoSmithKline Plc

Globavir Biosciences, Inc.

Immunovo BV

Jiangsu Hengrui Medicine Co., Ltd.

Jounce Therapeutics, Inc.

MacroGenics, Inc.

MedImmune, LLC

Merck & Co., Inc.

Merus B.V.

Novartis AG

Ono Pharmaceutical Co., Ltd.

Pfizer Inc.

PharmaEssentia Corporation

Regeneron Pharmaceuticals, Inc.

Sorrento Therapeutics, Inc.

Sutro Biopharma, Inc.

Symphogen A/S

Tasly Pharmaceutical Group Co., Ltd.

Tesaro, Inc.

Theravectys SA

Tikcro Technologies, Ltd.

Vyriad

Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) - Drug Profiles

AM-0001 - Drug Profile

AMP-224 - Drug Profile

AUR-012 - Drug Profile

BGB-108 - Drug Profile

BGBA-317 - Drug Profile

Biologic to Antagonize CTLA4 and PD-1 for Solid Tumor - Drug Profile

durvalumab + MEDI-0680 - Drug Profile

ENUM-388D4 - Drug Profile

GXP-2 - Drug Profile

inebilizumab + MEDI-0680 - Drug Profile

MCLA-134 - Drug Profile

mDX-400 - Drug Profile

MEDI-0680 - Drug Profile

MGD-013 - Drug Profile

Monoclonal Antibodies to Antagonize PD-1 for Oncology - Drug Profile

Monoclonal Antibodies to Antagonize PD-1 for Oncology - Drug Profile

Monoclonal Antibodies to Antagonize PD1 for Metastatic Melanoma and Metastatic Lung Cancer - Drug Profile

Monoclonal Antibodies to Inhibit CTLA4 and PD-1 for Oncology - Drug Profile

Monoclonal Antibodies to Inhibit PD-1 for Lung Adenocarcinoma - Drug Profile

Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections - Drug Profile

Monoclonal Antibody to Antagonize PD-1 for Non-Small Cell Lung Cancer - Drug Profile

Monoclonal Antibody to Antagonize PD-1 for Oncology - Drug Profile

Monoclonal Antibody to Antagonize PD-1 for Oncology - Drug Profile

Monoclonal Antibody to Antagonize PD-1 for Oncology - Drug Profile

Monoclonal Antibody to Antagonize PD1 for Oncology - Drug Profile

Monoclonal Antibody to Inhibit PD-1 and LAG3 for Oncology - Drug Profile

Monoclonal Antibody to Inhibit PD-1 and TIM3 for Oncology - Drug Profile

Monoclonal Antibody to Inhibit PD-1 for Cancer - Drug Profile

Monoclonal Antibody to Inhibit PD-1 for HIV - Drug Profile

Monoclonal Antibody to Inhibit PD-1 for Oncology - Drug Profile

nivolumab - Drug Profile

Oncolytic Virus for Lung Cancer - Drug Profile

Oncolytic Virus to Activate IFNb for Head and Neck Cancer and Lewis Lung Cancer - Drug Profile

pazopanib hydrochloride + pembrolizumab - Drug Profile

PD-1 Antagonist + ropeginterferon alfa-2b - Drug Profile

PDR-001 - Drug Profile

PEGMP-7 - Drug Profile

pembrolizumab - Drug Profile

PF-06801591 - Drug Profile

REGN-2810 - Drug Profile

SHR-1210 - Drug Profile

Small Molecule to Antagonize PD-1 for Oncology - Drug Profile

STIA-1110 - Drug Profile

TSR-042 - Drug Profile

Vaccine to Target CD274 and CD279 for Bladder Cancer - Drug Profile

Vaccine to Target CD274 and CD279 for Colorectal Cancer - Drug Profile

Vaccine to Target CD274 and CD279 for Renal Cell Carcinoma - Drug Profile

Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) - Dormant Projects

Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) - Discontinued Products

Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) - Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Comparative Analysis by Unknown Stage Development, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Development by Companies, H1 2016 (Contd..3)

Products under Development by Companies, H1 2016 (Contd..4)

Products under Development by Companies, H1 2016 (Contd..5)

Products under Development by Companies, H1 2016 (Contd..6)

Products under Development by Companies, H1 2016 (Contd..7)

Products under Development by Companies, H1 2016 (Contd..8)

Products under Development by Companies, H1 2016 (Contd..9)

Products under Development by Companies, H1 2016 (Contd..10)

Products under Development by Companies, H1 2016 (Contd..11)

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Agenus, Inc., H1 2016

Pipeline by Aurigene Discovery Technologies Limited, H1 2016

Pipeline by BeiGene, Ltd., H1 2016

Pipeline by Cellular Biomedicine Group, Inc., H1 2016

Pipeline by CytomX Therapeutics, Inc., H1 2016

Pipeline by Enumeral Biomedical Holdings, Inc., H1 2016

Pipeline by GlaxoSmithKline Plc, H1 2016

Pipeline by Globavir Biosciences, Inc., H1 2016

Pipeline by Immunovo BV, H1 2016

Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016

Pipeline by Jounce Therapeutics, Inc., H1 2016

Pipeline by MacroGenics, Inc., H1 2016

Pipeline by MedImmune, LLC, H1 2016

Pipeline by Merck & Co., Inc., H1 2016

Pipeline by Merus B.V., H1 2016

Pipeline by Novartis AG, H1 2016

Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016

Pipeline by Pfizer Inc., H1 2016

Pipeline by PharmaEssentia Corporation, H1 2016

Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016

Pipeline by Sorrento Therapeutics, Inc., H1 2016

Pipeline by Sutro Biopharma, Inc., H1 2016

Pipeline by Symphogen A/S, H1 2016

Pipeline by Tasly Pharmaceutical Group Co., Ltd., H1 2016

Pipeline by Tesaro, Inc., H1 2016

Pipeline by Theravectys SA, H1 2016

Pipeline by Tikcro Technologies, Ltd., H1 2016

Pipeline by Vyriad, H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Agenus, Inc.
  • GlaxoSmithKline Plc
  • MacroGenics, Inc.
  • Merus B.V.
  • Sutro Biopharma, Inc.
  • Theravectys SA
  • MORE
Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) Programmed cell death protein 1 also known as PD-1 and CD279 is a protein that encoded by the PDCD1 gene. PD-1 is a cell surface receptor that belongs to the immunoglobulin superfamily and is expressed on T cells and pro-B cells. PD-1 functioning as an immune checkpoint plays an important role in down regulating the immune system by preventing the activation of T-cells, which in turn reduces autoimmunity and promotes self-tolerance. The inhibitory effect of PD-1 is accomplished through a dual mechanism of promoting apoptosis (programmed cell death) in antigen specific T-cells in lymph nodes while simultaneously reducing apoptosis in regulatory T cells (suppressor T cells).

Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) pipeline Target constitutes close to 47 molecules. Out of which approximately 45 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 4, 7, 1, 21, 8 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Our latest report Programmed Cell Death Protein 1 – Pipeline Review, H1 2016, outlays comprehensive information on the Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Agenus, Inc.
Aurigene Discovery Technologies Limited
BeiGene, Ltd.
Cellular Biomedicine Group, Inc.
CytomX Therapeutics, Inc.
Enumeral Biomedical Holdings, Inc.
GlaxoSmithKline Plc
Globavir Biosciences, Inc.
Immunovo BV
Jiangsu Hengrui Medicine Co., Ltd.
Jounce Therapeutics, Inc.
MacroGenics, Inc.
MedImmune, LLC
Merck & Co., Inc.
Merus B.V.
Novartis AG
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
PharmaEssentia Corporation
Regeneron Pharmaceuticals, Inc.
Sorrento Therapeutics, Inc.
Sutro Biopharma, Inc.
Symphogen A/S
Tasly Pharmaceutical Group Co., Ltd.
Tesaro, Inc.
Theravectys SA
Tikcro Technologies, Ltd.
Vyriad
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll